A Phase 3 interventional study of ranibizumab in Age-related Macular Degeneration (AMD), sponsored by Bioeq GmbH. Completed at 58 sites in 12 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2021-09-30.
Sponsored by Bioeq GmbH · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.
Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 8th largest by enrollment of the 124 interventional ones that give a count, is one of 7 that started in 2015, is one of 31 in phase 3, and was the 104th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Austria, Czechia, Denmark and 10 more countries
Ages 50+
AO GENERIUM · Sites in Russian Federation
Ages 50+
AbbVie · Sites in United States
By country, each count listing its studies:
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 43 · Phase 3 35 · Phase 4 33
First in 2002; this study’s year is marked. 7 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 712 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 64 across the 124 interventional studies. Of the 98 that completed or were terminated, 42 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 125 have an industry lead sponsor. The 10 most frequent:
Bioeq GmbH is the lead sponsor of 3 studies on the registry; none are open to participants now.
Bioeq GmbH has 2 studies filed under Macular Degeneration — fewer than ten, so there is no comparison to draw.
3 of the studies testing ranibizumab in Macular Degeneration that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04657289Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) | 2027-02-04 |
| NCT05562947Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD) | 2027-06-30 |
| NCT04853251Genentech, Inc.A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) | 2027-07-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 125 studies testing ranibizumab in Macular Degeneration, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the efficacy and safety of the biosimilar ranibizumab FYB201 in comparison to Lucentis in patients with neovascular age-related macular degeneration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FYB201 is provided as single use vials and will be administered by intra-vitreal injection.
Biological: ranibizumab
Lucentis® is provided as single use vials and will be administered by intra-vitreal injection.
Biological: ranibizumab
Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 8 Weeks
The primary endpoint was the absolute change from baseline in BCVA by Early Treatment Diabetic Retinopathy Study (ETDRS) letters after 2 months (8 weeks) of treatment.
Time frame: Baseline and Week 8
Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 24 Weeks
Absolute change from baseline in BCVA by Early Treatment Diabetic Retinopathy Study (ETDRS) letters after 24 weeks of treatment.
Time frame: Baseline and Week 24
Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 48 Weeks
Absolute change from baseline in BCVA by Early Treatment Diabetic Retinopathy Study (ETDRS) letters after 48 weeks of treatment.
Time frame: Baseline and Week 48
Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 12 Months
Absolute change from baseline in BCVA by Early Treatment Diabetic Retinopathy Study (ETDRS) letters after 12 months, calculated as the average of the changes from baseline to Week 40, to Week 44 and to Week 48.
Time frame: Baseline and 12 Months
Change in Foveal Centre Point (FCP) Retinal Thickness From Baseline to Week 24
Absolute change in Foveal Centre Point (FCP) retinal thickness \[µm\] from baseline to Week 24
Time frame: Baseline and Week 24
Change in Foveal Centre Point (FCP) Retinal Thickness From Baseline to Week 48
Absolute change in Foveal Centre Point (FCP) retinal thickness \[µm\] from baseline to Week 48
Time frame: Baseline and Week 48
Change in Foveal Central Subfield (FCS) Retinal Thickness From Baseline to Week 24
Absolute change in Foveal Central Subfield (FCS) retinal thickness \[µm\] from baseline to Week 24
Time frame: Baseline and Week 24
Change in Foveal Central Subfield (FCS) Retinal Thickness From Baseline to Week 48
Absolute change in Foveal Central Subfield (FCS) retinal thickness \[µm\] from baseline to Week 48
Time frame: Baseline and Week 48
Change in Total Lesion Area From Baseline to Week 24
Absolute change in total lesion area \[mm²\] from baseline to Week 24
Time frame: Baseline and Week 24
Change in Total Lesion Area From Baseline to Week 48
Absolute change in total lesion area \[mm²\] from baseline to Week 48
Time frame: Baseline and Week 48
Change in NEI VFQ-25 Composite Score From Baseline to Week 24
Absolute change from baseline to Week 24 in vision-related functioning and well-being measured by the National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25) composite score. The NEI VFQ-25 is a 25 question quality of life questionnaire with possible item scores between 0 and 100. Higher scores represent better functioning. The composite score is calculated as average over all non-missing item scores.
Time frame: Baseline and Week 24
Change in NEI VFQ-25 Composite Score From Baseline to Week 48
Absolute change from baseline to Week 48 in vision-related functioning and well-being measured by the National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25) composite score. The NEI VFQ-25 is a 25 question quality of life questionnaire with possible item scores between 0 and 100. Higher scores represent better functioning. The composite score is calculated as average over all non-missing item scores.
Time frame: Baseline and Week 48
Active CNV Leakage at Week 24
Number and percentage of patients with active CNV leakage at Week 24
Time frame: Baseline and Week 24
Active CNV Leakage at Week 48
Number and percentage of patients with active CNV leakage at Week 48
Time frame: Baseline and Week 48
Fluid-free Macula at Each Visit
Number and percentage of patients with fluid-free macula at each visit
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48
Anti-drug Antibodies by Scheduled eCRF Visit
Frequency of patients with anti-drug antibodies (ADAs) by scheduled eCRF visit
Time frame: Baseline and Weeks 1, 4, 12, 24, 48
Anti-drug Antibodies Pre- and Post-first Dosing
Number and percentage of patients with detection of anti-drug antibodies (ADAs) pre-first dosing and post-first dosing (combination of all ADA assessments after first injection of study medication).
Time frame: Baseline and up to Week 48
| Milestone | FYB201 | Lucentis |
|---|---|---|
| Started | 238 | 239 |
| Completed | 226 | 226 |
| Not completed | 12 | 13 |
| Withdrew: Withdrawal by subject | 2 | 8 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Death | 2 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Lost to follow-up | 3 | 1 |
| Withdrew: Need for alternative treatment | 1 | 0 |
| Withdrew: Other reason | 2 | 1 |
The primary endpoint was the absolute change from baseline in BCVA by Early Treatment Diabetic Retinopathy Study (ETDRS) letters after 2 months (8 weeks) of treatment.
| letters | FYB201 | Lucentis | Total |
|---|---|---|---|
| Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 8 Weeks | 5.1 ± 7.52 | 5.6 ± 8.63 | 5.4 ± 8.10 |
Absolute change from baseline in BCVA by Early Treatment Diabetic Retinopathy Study (ETDRS) letters after 24 weeks of treatment.
| letters | FYB201 | Lucentis | Total |
|---|---|---|---|
| Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 24 Weeks | 6.9 ± 10.12 | 7.1 ± 10.42 | 7.0 ± 10.26 |
Absolute change from baseline in BCVA by Early Treatment Diabetic Retinopathy Study (ETDRS) letters after 48 weeks of treatment.
| letters | FYB201 | Lucentis | Total |
|---|---|---|---|
| Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 48 Weeks | 7.8 ± 11.67 | 8.0 ± 11.31 | 7.9 ± 11.48 |
Absolute change from baseline in BCVA by Early Treatment Diabetic Retinopathy Study (ETDRS) letters after 12 months, calculated as the average of the changes from baseline to Week 40, to Week 44 and to Week 48.
| letters | FYB201 | Lucentis | Total |
|---|---|---|---|
| Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 12 Months | 7.8 ± 11.19 | 7.9 ± 11.01 | 7.8 ± 11.09 |
Absolute change in Foveal Centre Point (FCP) retinal thickness \[µm\] from baseline to Week 24
| µm | FYB201 | Lucentis | Total |
|---|---|---|---|
| Change in Foveal Centre Point (FCP) Retinal Thickness From Baseline to Week 24 | -203.94 ± 147.104 | -205.45 ± 147.199 | -204.70 ± 146.986 |
Absolute change in Foveal Centre Point (FCP) retinal thickness \[µm\] from baseline to Week 48
| µm | FYB201 | Lucentis | Total |
|---|---|---|---|
| Change in Foveal Centre Point (FCP) Retinal Thickness From Baseline to Week 48 | -213.26 ± 161.323 | -211.02 ± 151.950 | -212.14 ± 156.521 |
Absolute change in Foveal Central Subfield (FCS) retinal thickness \[µm\] from baseline to Week 24
| µm | FYB201 | Lucentis | Total |
|---|---|---|---|
| Change in Foveal Central Subfield (FCS) Retinal Thickness From Baseline to Week 24 | -180.37 ± 128.522 | -181.63 ± 126.466 | -181.02 ± 127.330 |
Absolute change in Foveal Central Subfield (FCS) retinal thickness \[µm\] from baseline to Week 48
| µm | FYB201 | Lucentis | Total |
|---|---|---|---|
| Change in Foveal Central Subfield (FCS) Retinal Thickness From Baseline to Week 48 | -182.85 ± 134.588 | -190.75 ± 128.691 | -186.86 ± 131.532 |
Absolute change in total lesion area \[mm²\] from baseline to Week 24
| mm² | FYB201 | Lucentis | Total |
|---|---|---|---|
| Change in Total Lesion Area From Baseline to Week 24 | -0.5742 ± 4.79222 | -0.7113 ± 5.35854 | -0.6418 ± 5.07361 |
Absolute change in total lesion area \[mm²\] from baseline to Week 48
| mm² | FYB201 | Lucentis | Total |
|---|---|---|---|
| Change in Total Lesion Area From Baseline to Week 48 | -0.6382 ± 4.81194 | -1.1814 ± 5.42770 | -0.9123 ± 5.13128 |
Absolute change from baseline to Week 24 in vision-related functioning and well-being measured by the National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25) composite score. The NEI VFQ-25 is a 25 question quality of life questionnaire with possible item scores between 0 and 100. Higher scores represent better functioning. The composite score is calculated as average over all non-missing item scores.
| score on a scale | FYB201 | Lucentis | Total |
|---|---|---|---|
| Change in NEI VFQ-25 Composite Score From Baseline to Week 24 | 3.59 ± 9.632 | 3.55 ± 11.237 | 3.57 ± 10.457 |
Absolute change from baseline to Week 48 in vision-related functioning and well-being measured by the National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25) composite score. The NEI VFQ-25 is a 25 question quality of life questionnaire with possible item scores between 0 and 100. Higher scores represent better functioning. The composite score is calculated as average over all non-missing item scores.
| score on a scale | FYB201 | Lucentis | Total |
|---|---|---|---|
| Change in NEI VFQ-25 Composite Score From Baseline to Week 48 | 5.30 ± 12.205 | 3.75 ± 13.190 | 4.53 ± 12.714 |
Number and percentage of patients with active CNV leakage at Week 24
| Participants | FYB201 | Lucentis | Total |
|---|---|---|---|
| CNV leakage | 115 | 111 | 226 |
| No CNV leakage | 106 | 108 | 214 |
Number and percentage of patients with active CNV leakage at Week 48
| Participants | FYB201 | Lucentis | Total |
|---|---|---|---|
| CNV leakage | 119 | 115 | 234 |
| No CNV leakage | 92 | 81 | 173 |
Number and percentage of patients with fluid-free macula at each visit
| Participants | FYB201 | Lucentis | Total |
|---|---|---|---|
| Baseline — Fluid-free macula | 0 | 2 | 2 |
| Baseline — No fluid-free macula | 236 | 234 | 470 |
| Week 4 — Fluid-free macula | 43 | 38 | 81 |
| Week 4 — No fluid-free macula | 187 | 188 | 375 |
| Week 8 — Fluid-free macula | 69 | 62 | 131 |
| Week 8 — No fluid-free macula | 154 | 168 | 322 |
| Week 12 — Fluid-free macula | 86 | 76 | 162 |
| Week 12 — No fluid-free macula | 141 | 155 | 296 |
| Week 16 — Fluid-free macula | 87 | 87 | 174 |
| Week 16 — No fluid-free macula | 136 | 149 | 285 |
| Week 20 — Fluid-free macula | 80 | 97 | 177 |
| Week 20 — No fluid-free macula | 146 | 137 | 283 |
| Week 24 — Fluid-free macula | 86 | 100 | 186 |
| Week 24 — No fluid-free macula | 141 | 131 | 272 |
| Week 28 — Fluid-free macula | 86 | 98 | 184 |
| Week 28 — No fluid-free macula | 140 | 121 | 261 |
| Week 32 — Fluid-free macula | 91 | 96 | 187 |
| Week 32 — No fluid-free macula | 131 | 125 | 256 |
| Week 36 — Fluid-free macula | 83 | 99 | 182 |
| Week 36 — No fluid-free macula | 142 | 119 | 261 |
| Week 40 — Fluid-free macula | 87 | 102 | 189 |
| Week 40 — No fluid-free macula | 133 | 115 | 248 |
| Week 44 — Fluid-free macula | 92 | 104 | 196 |
| Week 44 — No fluid-free macula | 129 | 116 | 245 |
| Week 48 — Fluid-free macula | 105 | 108 | 213 |
| Week 48 — No fluid-free macula | 120 | 113 | 233 |
Frequency of patients with anti-drug antibodies (ADAs) by scheduled eCRF visit
| Participants | FYB201 | Lucentis | Total |
|---|---|---|---|
| Baseline — Positive anti-drug antibodies | 0 | 5 | 5 |
| Baseline — Negative anti-drug antibodies | 234 | 233 | 467 |
| Week 1 — Positive anti-drug antibodies | 0 | 0 | 0 |
| Week 1 — Negative anti-drug antibodies | 28 | 29 | 57 |
| Week 4 — Positive anti-drug antibodies | 2 | 2 | 4 |
| Week 4 — Negative anti-drug antibodies | 224 | 226 | 450 |
| Week 12 — Positive anti-drug antibodies | 1 | 2 | 3 |
| Week 12 — Negative anti-drug antibodies | 225 | 224 | 449 |
| Week 24 — Positive anti-drug antibodies | 6 | 6 | 12 |
| Week 24 — Negative anti-drug antibodies | 219 | 219 | 438 |
| Week 48 — Positive anti-drug antibodies | 9 | 12 | 21 |
| Week 48 — Negative anti-drug antibodies | 220 | 213 | 433 |
Number and percentage of patients with detection of anti-drug antibodies (ADAs) pre-first dosing and post-first dosing (combination of all ADA assessments after first injection of study medication).
| Participants | FYB201 | Lucentis | Total |
|---|---|---|---|
| Pre-first dosing — Positive anti-drug antibodies | 0 | 5 | 5 |
| Pre-first dosing — Negative anti-drug antibodies | 232 | 231 | 463 |
| Post-first dosing — Positive anti-drug antibodies | 14 | 14 | 28 |
| Post-first dosing — Negative anti-drug antibodies | 223 | 224 | 447 |
Collected over From first treatment up to Week 48. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FYB201 | 2/238 (0.8%) | 19/238 (8%) | 149/238 (62.6%) |
| Lucentis | 1/239 (0.4%) | 32/239 (13.4%) | 161/239 (67.4%) |
| Event | FYB201 | Lucentis |
|---|---|---|
| Atrial fibrillationCardiac disorders | 3/238 | 1/239 |
| Acute kidney injuryRenal and urinary disorders | 2/238 | 0/239 |
| Myocardial infarctionCardiac disorders | 1/238 | 2/239 |
| CataractEye disorders | 0/238 | 2/239 |
| EndophthalmitisInfections and infestations | 1/238 | 2/239 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/238 | 2/239 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/238 | 2/239 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/238 | 2/239 |
| Anaemia macrocyticBlood and lymphatic system disorders | 1/238 | 0/239 |
| Atrial flutterCardiac disorders | 1/238 | 0/239 |
| Event | FYB201 | Lucentis |
|---|---|---|
| Neovascular age-related macular degenerationEye disorders | 19/238 | 22/239 |
| Conjunctival haemorrhageEye disorders | 14/238 | 19/239 |
| NasopharyngitisInfections and infestations | 12/238 | 16/239 |
| HypertensionVascular disorders | 3/238 | 14/239 |
| Punctate keratitisEye disorders | 8/238 | 12/239 |
| Intraocular pressure increasedInvestigations | 11/238 | 12/239 |
| Visual acuity reducedEye disorders | 6/238 | 11/239 |
| C-reactive protein increasedInvestigations | 10/238 | 5/239 |
| CataractEye disorders | 1/238 | 10/239 |
| Eye painEye disorders | 9/238 | 6/239 |
Safety Set (SAF): The safety set comprised all patients who had received at least one injection with investigational medicinal product.
| Age, Continuous(years) | FYB201 | Lucentis | Total |
|---|---|---|---|
| Mean | 74.9 ± 8.26 | 76.1 ± 7.84 | 75.5 ± 8.07 |
| Sex: Female, Male(Participants) | FYB201 | Lucentis | Total |
|---|---|---|---|
| Female | 135 | 134 | 269 |
| Male | 103 | 105 | 208 |
| Race (NIH/OMB)(Participants) | FYB201 | Lucentis | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 2 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 236 | 233 | 469 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 4 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2015 to primary completion in Dec 2017, 24 months.
Results were first posted in Sep 2021, 3 years 9 months after primary completion.
Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 24 months is close to that.
Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab
Bioeq GmbH